- HER2 negative
- PD-L1 positive
- ER positive
- HER2 positive
- EGFR negative
- EGFR positive
- PR positive
- ALK negative
- KRAS positive
- PD-L1 negative
- BRAF positive
- ER negative
- PR negative
- BRAF negative
- BRCA1 positive
- ROS1 negative
- BRCA2 positive
- p16 positive
- CD20 positive
- ALK positive
- HLA positive
- PIK3CA positive
- MET positive
- ROS1 positive
- HLA-A positive
- HR positive
- IDH negative
- MYC positive
- PALB2 positive
- TP53 positive
- p16 negative
- MET negative
- RET positive
- BCR-ABL1 positive
- HBsAg positive
- NRAS positive
- RET negative
- TP53 negative
- anti-dsDNA positive
- ABCA4 positive
- ANA positive
- BCL2 positive
- CCND1 positive
- CFTR positive
- HLA negative
- HLA-A negative
- HPV negative
- IDH positive
- KRAS negative
- MSS positive
- NTRK negative
- NTRK positive
- RAS positive
- RB1 negative
- RB1 positive
- dMMR positive
- APP positive
- BCL6 positive
- BRCA positive
- BRCA1 negative
- BRCA2 negative
- COL7A1 positive
- FMR1 positive
- MDM2 positive
- MGMT negative
- MSI-H positive
- NF1 positive
- PSEN1 positive
- PSEN2 positive
- PTEN positive
- Philadelphia chromosome positive
- RAS negative
- RF positive
- RHO positive
- TROP2 negative
- TROP2 positive
- ctDNA positive
- pMMR positive
- 11q negative
- 11q positive
- AKT negative
- ALPL positive
- ATM positive
- Anti-PLA2R positive
- Aβ1-42 positive
- C5 positive
- CLDN18.2 positive
- DLL3 positive
- DMD positive
- EBV positive
- FOXO1 fusion negative
- GRN positive
- HBB positive
- HEXA positive
- HEXB positive
- HPV positive
- HPV16 positive
- HRAS positive
- IGHV positive
- JAK2 positive
- KIT positive
- MGMT positive
- MLH1 positive
- MMR positive
- MSH2 positive
- MSH6 positive
- MSI-H negative
- NF2 positive
- NRAS negative
- PDE6A positive
- PDE6B positive
- PIK3CA negative
- PIK3CD positive
- PIK3R1 positive
- PMM2 positive
- PMS2 positive
- PTCH1 positive
- PTEN negative
- PiZZ positive
- RAF positive
- SPINK5 positive
- T790M positive
- TTR positive
- anti-Ro autoantibodies positive
- anti-Ro/SSA positive
- anti-Sm positive
- anti-Smith positive
- dMMR negative
- t(11;14) positive
- 12 negative
- 12 positive
- 13q negative
- 13q positive
- 16p11.2 deletion positive
- 17p negative
- 17p positive
- 19q negative
- 19q positive
- 1p negative
- 1p positive
- 1p/19q co-deletion positive
- 1p/19q loss positive
- 1p36 deletion positive
- 46 XX karyotype positive
- 5q SMA positive
- 5q-autosomal recessive SMA positive
- AAVrh74 antibody titers negative
- ABL-class fusion positive
- ABL-class fusions positive
- ABO negative
- ABO positive
- ACVR1 positive
- AChR positive
- AChR-Ab positive
- ADAMTS-13 negative
- ADAMTS-13 positive
- AFP positive
- AKT positive
- AKT1 positive
- APOL1 positive
- Acetylcholine receptor antibody positive
- Anti-CCP-2 positive
- Anti-HBc IgM negative
- Anti-Ro/SS-A positive
- Anti-SSA (Ro) positive
- Anti-SSB (La) positive
- Anti-Smith antibodies positive
- Antinuclear antibody positive
- Aβ1-40 positive
- Aβ1-42/Aβ1-40 ratio positive
- B7-H6 positive
- BCL-2 positive
- BCL-6 positive
- BCR-ABL1 e13a2 positive
- BCR-ABL1 e14a2 positive
- BCR-ABL1 fusion positive
- BCR-ABL1IS positive
- BTK-C481 positive
- C1-INH functional activity positive
- C1-INH positive
- C10orf2 positive
- C4 antigen level positive
- C5 p.Arg885Cys positive
- C5 p.Arg885His positive
- C9orf72 positive
- CAG expansion positive
- CAG repeat in HTT positive
- CASR positive
- CCND2 positive
- CCND3 positive
- CCNE1 positive
- CD123 positive
- CD19 positive
- CD20 negative
- CD25 positive
- CD30 negative
- CD30 positive
- CD4 count negative
- CD4 count positive
- CD4 negative
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1927nm Fractional Thulium Laser Treatment
- Adjuvant Therapy (except reconstruction)
- Anti-Seizure Medications (up to 2 types)
- Any Treatment for Pancreatic Cancer
- At least one prior tumor-directed therapy
- Avoidance of Activities That Cause Joint Pain
- Biologic Anti-Neoplastic Agent
- CD4+ > 350 cells/microliter for at least twelve months
- Cancer-Directed Surgery
- Cellular Therapies for ALS
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
3072 trials
Trials Without a Placebo
1
2
3
…50